Abbvie Inc
NYSE:ABBV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
137.6
197.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Abbvie Inc
Abbvie Inc
Revenue
Abbvie Inc
Revenue Peer Comparison
GILD
AMGN
ALNY
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$30.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Revenue
$2.3B
|
CAGR 3-Years
51%
|
CAGR 5-Years
88%
|
CAGR 10-Years
52%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
25%
|
CAGR 10-Years
29%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
Abbvie Inc
Revenue Breakdown
Breakdown by Geography
Abbvie Inc
|
Total Revenue:
54.3B
USD
|
|
United States:
41.9B
USD
|
|
Other Countries:
5B
USD
|
|
Germany:
1.3B
USD
|
|
Canada:
1.1B
USD
|
|
Japan:
1B
USD
|
|
China:
950m
USD
|
|
France:
780m
USD
|
|
Spain:
501m
USD
|
|
Italy:
484m
USD
|
|
Australia:
472m
USD
|
|
Brazil:
439m
USD
|
Breakdown by Segments
Abbvie Inc
|
Total Revenue:
54.3B
USD
|
|
H U M I R A:
14.4B
USD
|
|
Skyrizi:
7.8B
USD
|
|
Rinvoq:
4B
USD
|
|
Imbruvica:
3.6B
USD
|
|
Other Products:
3B
USD
|
|
Botox Therapeutic:
3B
USD
|
|
Vraylar:
2.8B
USD
|
|
Botox Cosmetic:
2.7B
USD
|
|
Venclexta:
2.3B
USD
|
|
Mavyret:
1.4B
USD
|
|
Juvederm Collection:
1.4B
USD
|
|
Other Aesthetics:
1.2B
USD
|
|
Linzess/Constella:
1.1B
USD
|
|
Ubrelvy:
815m
USD
|
|
Other Eye Care:
803m
USD
|
|
Ozurdex:
472m
USD
|
|
Duodopa:
468m
USD
|
|
Restasis:
436m
USD
|
|
Lumigan/Ganfort:
432m
USD
|
|
Qulipta:
408m
USD
|
|
Other Neuroscience:
276m
USD
|
|
Alphagan/Combigan:
272m
USD
|
See Also
What is Abbvie Inc's Revenue?
Revenue
55B
USD
Based on the financial report for Jun 30, 2024, Abbvie Inc's Revenue amounts to 55B USD.
What is Abbvie Inc's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Abbvie Inc have been 1% over the past three years , 11% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
